Cost Effectiveness of the Third-Generation Tyrosine Kinase Inhibitor (TKI) Ponatinib, vs. Second-Generation TKIs or Stem Cell Transplant, as Third-Line Treatment for Chronic-Phase Chronic Myeloid…

Overview of attention for article published in Applied Health Economics and Health Policy, June 2019

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (63rd percentile)
Above-average Attention Score compared to outputs of the same age and source (60th percentile)

Mentioned by

policy: 1 policy source
twitter: 1 X user

facebook: 1 Facebook page

Readers on

mendeley: 29 Mendeley

Summary Policy documents X Facebook

So far, Altmetric has seen 1 policy document that references this research output.

pembrolizumab

Cited by Canadian Agency for Drugs and Technologies in Health on 14 Dec 2021

CADTH is an independent, not-for-profit organization responsible for providing health care decision-makers with objective evidence to help make informed decisions about the optimal use of health technologies.

This page shows the most recent policy documents that mention this research output.

Click here to find out how to access more activity.